Comparative Pharmacology
Head-to-head clinical analysis: ELAVIL versus IMIPRAMINE PAMOATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ELAVIL versus IMIPRAMINE PAMOATE.
ELAVIL vs IMIPRAMINE PAMOATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Amitriptyline inhibits the reuptake of serotonin and norepinephrine in the central nervous system, increasing their synaptic concentrations. It also exhibits anticholinergic, antihistaminergic, and alpha-adrenergic blocking effects.
Imipramine is a tricyclic antidepressant that inhibits the reuptake of norepinephrine and serotonin at presynaptic neuronal membranes, increasing their concentrations in the synaptic cleft. It also has anticholinergic, antihistaminergic, and alpha-adrenergic blocking effects.
Oral: Initial 75 mg/day in divided doses or 50-100 mg at bedtime; increase to 150 mg/day; maximum 300 mg/day. IM: 20-30 mg q6h, switch to oral as soon as possible.
150-300 mg orally once daily at bedtime for depression; 75-150 mg/day for panic disorder.
None Documented
None Documented
10–50 hours (mean ~20 hours); terminal elimination half-life is prolonged in elderly and patients with hepatic impairment; steady-state achieved in 7–21 days.
11-25 hours (mean 19 h); extended in elderly (up to 30 h) and hepatic impairment; clinical context: steady-state reached in 7-14 days
Renal (approximately 40% as metabolites, <5% unchanged); biliary/fecal (approximately 60% as metabolites, including glucuronide conjugates).
Primarily renal (70% as metabolites, <5% unchanged); 20-30% fecal via biliary excretion
Category C
Category C
Tricyclic Antidepressant
Tricyclic Antidepressant